Blueshift Asset Management, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Blueshift Asset Management, LLC

  • $267 Million
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$38.96 - $42.75 $157,943 - $173,308
4,054 Added 60.18%
10,791 $441,000
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $275,408 - $291,509
6,737 New
6,737 $284,000
Q2 2022

Aug 12, 2022
SELL
$20.62 - $37.15 $211,726 - $381,456
-10,268 Closed
0 $0
Q1 2022

May 12, 2022
BUY
$23.5 - $35.38 $241,298 - $363,281
10,268 New
10,268 $359,000

Others Institutions Holding CERE

# of Institutions
7
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Blueshift Asset Management, LLC Portfolio

Follow Blueshift Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueshift Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email